Provigil ADHD Application Likely To Be Reviewed By New Neurological Division
This article was originally published in The Pink Sheet Daily
Executive Summary
Cephalon expects continuity of review for Provigil's additional indication despite FDA's reorganization. The company has three upcoming filings that could be affected by the proposed split of the neuropharm division.